Parkinson hastalığının ve Crohn hastalığının bağırsak-kan-beyin ekseni boyunca komorbid manzarasını haritalamak
Mapping the comorbid landscape of Parkinson’s disease and Crohn’s disease along the gut-blood-brain axis
DOI: 10.1101/2025.10.01.25337087
Mapping the comorbid landscape of Parkinson’s disease and Crohn’s disease along the gut-blood-brain axis
DOI: 10.1101/2025.10.01.25337087
A Multi-Modal Framework Combining Proteomics, Electrophysiology, and Clinical Phenotypes to Characterize Neuroplasticity in Parkinson’s Disease Rehabilitation
DOI: 10.21203/rs.3.rs-7527339/v1
Integrative lipidomics of brain and plasma uncovers sex-specific metabolic signatures in Parkinson’s disease
DOI: 10.1101/2025.10.02.679990
Efficacy of eHealth interventions in patients with Parkinson's disease: A protocol for systematic review and network meta–analysis
DOI: 10.21203/rs.3.rs-6768944/v1
Living Alone Is Associated with Discontinuation of Levodopa-Entacapone-Carbidopa Intestinal Gel Treatment in Advanced Parkinson's Disease.
DOI: 10.1159/000548570PMID: 41042721
Rotenone accelerates endogenous α-synuclein spreading and enhances neurodegeneration in an intra-striatal α-synuclein preformed fibril injected mouse model of Parkinson's disease.
DOI: 10.3389/fncel.2025.1624593PMID: 41114126
Social experiences of people living with Parkinson's disease in Ireland: A qualitative study.
DOI: 10.1016/j.prdoa.2025.100397PMID: 41140781
Evaluating Parkinson's disease biomarkers in substantia nigra following sublethal γ-radiation exposure in a large animal model.
DOI: 10.1038/s41531-025-01136-3PMID: 41044307
Network mechanisms in rapid-onset dystonia-parkinsonism.
DOI: 10.1016/j.expneurol.2025.115491PMID: 41047113
Review of the Effects of Lifestyle Modification on Parkinson's Disease.
DOI: 10.1177/15598276251384591PMID: 41050191
Enhanced Detection and Segmentation of Sit Phases in Patients with Parkinson's Disease Using a Single SmartWatch and Random Forest Algorithms.
DOI: 10.3390/s25196104PMID: 41094927
Bolus MPTP Injection in Aged Mice to Mimic Parkinson Disease: Effects of Low-Dose Antioxidant Treatment with Fullerene (C<sub>60</sub>) and Fullerenol (C<sub>60</sub>(OH)<sub>24</sub>).
DOI: 10.3390/biomedicines13102425PMID: 41153708
Kayıtlar bilimsel kaynaklardan alınır. Bibliyografik kayıt sayısı, Türkçe çeviri veya editoryal onay sayısı değildir.